Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine Safety Extension in Pediatric Autism
NCT01999894Phase 2Completed
- Sponsor
- Forest Laboratories
- Start
- Nov 2009
- Primary completion
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of memantine in Autism Spectrum Disorder (ASD), sponsored by Forest Laboratories. Primary endpoint: Treatment-emergent Adverse Events at 48 weeks. Started Nov 2009; status: completed.
02
Drugs
memantine
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01999894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999894.